OncoMatch/Clinical Trials/NCT05068232
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
Is NCT05068232 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Durvalumab and Etoposide for small-cell lung cancer.
Treatment: Durvalumab · Etoposide · Carboplatin — This this study is for individuals who have treatment-naïve extensive-stage small cell lung cancer (small cell lung cancer that wont respond to treatment). Doctors leading this study hope to learn if combining durvalumab, carboplatin and etoposide with hyofractionated ablative radiation therapy (radiation focused on certain parts of the body) will help treat your cancer and improve how long you can live with extensive-stage small cell cancer without it getting worse (progression-free survival). Your participation in this research will last about 48 months. Durvalumab along with chemotherapy has been approved by the Food and Drug Administration (FDA) for the treatment of small cell lung cancer along with chemotherapy. This study is testing the addition of radiation to durvalumab and chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Has received prior chemotherapy ... for small cell lung cancer.
Cannot have received: immunotherapy
Has received prior ... immunotherapy ... for small cell lung cancer.
Cannot have received: thoracic radiation
Has received prior ... thoracic radiation for small cell lung cancer.
Cannot have received: anti-PD-1 therapy
Has prior exposure to anti-PD (Programmed death-ligand 1) 1/PD-L1 or anti- cytotoxic T lymphocyte-associated antigen (CTLA4) therapy.
Cannot have received: anti-PD-L1 therapy
Has prior exposure to anti-PD (Programmed death-ligand 1) 1/PD-L1 or anti- cytotoxic T lymphocyte-associated antigen (CTLA4) therapy.
Cannot have received: anti-CTLA-4 therapy
Has prior exposure to anti-PD (Programmed death-ligand 1) 1/PD-L1 or anti- cytotoxic T lymphocyte-associated antigen (CTLA4) therapy.
Cannot have received: radiation therapy
Exception: prior radiation therapy (>10% of prior prescription dose) to the area planning to be treated with trial RT
Has had prior radiation therapy (defined as >10% of prior prescription dose) to the area planning to be treated with trial RT.
Cannot have received: durvalumab (durvalumab)
Prior randomisation or treatment in a previous durvalumab clinical study regardless of treatment arm assignment.
Lab requirements
Blood counts
Adequate normal organ and marrow function as defined by lab values the study doctor will review.
Kidney function
Adequate normal organ and marrow function as defined by lab values the study doctor will review.
Liver function
Adequate normal organ and marrow function as defined by lab values the study doctor will review.
Adequate normal organ and marrow function as defined by lab values the study doctor will review.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Chicago Medicine · Chicago, Illinois
- University of Wisconsin Carbone Cancer Center · Madison, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify